A multicenter phase II trial of tumor treating fields plus chemotherapy for first-line treatment of gastric adenocarcinoma

被引：0
|
作者：
Li, Jin
Yeo, Winnie
Lam, Ka-On
机构：
[1] Fudan Univ, Shanghai Med Coll, Dept Oncol, Dept Med Oncol,Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Chinese Univ Hong Kong, Hong Kong, Peoples R China
[3] Univ Hong Kong, Shenzhen Hosp, Shenzhen, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS474
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer
    Scheithauer, W
    Kornek, GV
    Raderer, M
    Ulrich-Pur, H
    Fiebiger, W
    Gedlicka, C
    Schüll, B
    Brugger, S
    Schneeweiss, B
    Lang, F
    Lenauer, A
    Depisch, D
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) : 165 - 172
  • [22] Raltitrexed plus oxaliplatin as first-line chemotherapy in metastatic colorectal carcinoma: a multicentric phase II trial
    Neri, B
    Doni, L
    Fulignati, C
    Perfetto, F
    Turrini, M
    Andreoli, F
    Pantalone, D
    Pernice, LM
    Taruffi, F
    Martini, V
    Poma, A
    Valeri, A
    Bacci, G
    Sancez, L
    Moretti, R
    ANTI-CANCER DRUGS, 2002, 13 (07) : 719 - 724
  • [23] A Phase II Trial of Pictilisib with Chemotherapy in First-Line Squamous NSCLC
    Spigel, David
    Luft, Alexander
    Vynnychenko, Ihor
    Fadeeva, Natalia
    Mark, Zsuzsanna
    Ponce, Santiago
    Matrosova, Marina
    Goldschmidt, Jerome
    Szima, Barna
    Saleh, Mansoor
    Lackner, Mark
    Gendreau, Steve
    Bassett, Katia
    Spoerke, Jill
    Koeppen, Hartmut
    Gilbert, Houston
    Jin, Huan
    Shankar, Geetha
    Lin, Wei
    Denis, Fabrice
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S375 - S375
  • [24] Evaluation of second-line apatinib plus irinotecan as a treatment for advanced gastric adenocarcinoma or gastroesophageal conjunction adenocarcinoma: a prospective, multicenter phase II trial
    Qu, Jinglei
    He, Xin
    Luo, Ying
    Yu, Ping
    Chen, Ying
    Liu, Jing
    Wang, Xin
    Wang, Chang
    Liang, Tingting
    Bai, Yuxian
    Han, Yu
    Man, Li
    Leng, Chuanchun
    Zhou, Caiyun
    He, Lijie
    Liu, Yunpeng
    Qu, Xiujuan
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [25] A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma
    Rougier, P
    Adenis, A
    Ducreux, M
    de Forni, M
    Bonneterre, J
    Dembak, M
    Clouet, P
    Lebecq, A
    Baille, P
    Lefresne-Soulas, F
    Blanc, C
    Armand, JP
    EUROPEAN JOURNAL OF CANCER, 2000, 36 (08) : 1016 - 1025
  • [26] Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer
    F Cappuzzo
    F Mazzoni
    A Gennari
    S Donati
    B Salvadori
    C Orlandini
    G L Cetto
    A Molino
    E Galligioni
    M Mansutti
    S Tumolo
    A Lucentini
    F Valduga
    S Bartolini
    L Crinò
    P F Conte
    British Journal of Cancer, 2004, 90 : 31 - 35
  • [27] Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer
    Cappuzzo, F
    Mazzoni, F
    Gennari, A
    Donati, S
    Salvadori, B
    Orlandini, C
    Cetto, GL
    Molino, A
    Galligioni, E
    Mansutti, M
    Tumolo, S
    Lucentini, A
    Valduga, F
    Bartolini, S
    Crinò, L
    Conte, PF
    BRITISH JOURNAL OF CANCER, 2004, 90 (01) : 31 - 35
  • [28] Publisher Correction: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial
    Hai-Qiang Mai
    Qiu-Yan Chen
    Dongping Chen
    Chaosu Hu
    Kunyu Yang
    Jiyu Wen
    Jingao Li
    Ying-Rui Shi
    Feng Jin
    Ruilian Xu
    Jianji Pan
    Shenhong Qu
    Ping Li
    Chunhong Hu
    Yi-Chun Liu
    Yi Jiang
    Xia He
    Hung-Ming Wang
    Wan-Teck Lim
    Wangjun Liao
    Xiaohui He
    Xiaozhong Chen
    Zhigang Liu
    Xianglin Yuan
    Qi Li
    Xiaoyan Lin
    Shanghua Jing
    Yanju Chen
    Yin Lu
    Ching-Yun Hsieh
    Muh-Hwa Yang
    Chia-Jui Yen
    Jens Samol
    Hui Feng
    Sheng Yao
    Patricia Keegan
    Rui-Hua Xu
    Nature Medicine, 2022, 28 : 214 - 214
  • [29] Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)
    Yang, Yunpeng
    Pan, Jianji
    Wang, Hui
    Zhao, Yuanyuan
    Qu, Shenhong
    Chen, Nianyong
    Chen, Xiaozhong
    Sun, Yan
    He, Xiaohui
    Hu, Chaosu
    Lin, Lizhu
    Yu, Qitao
    Wang, Siyang
    Wang, Guihua
    Lei, Feng
    Wen, Jiyu
    Yang, Kunyu
    Lin, Zhixiong
    Guo, Ye
    Chen, Shaoqing
    Huang, Xiaoming
    Wu, Yanjie
    Liang, Liang
    Chen, Chenqi
    Bai, Fan
    Ma, Xiaopeng
    Zhang, Yun
    Leaw, Shiangjiin
    Zhang, Li
    Fang, Wenfeng
    CANCER CELL, 2023, 41 (06) : 1061 - +
  • [30] Efficacy and safety of modified ECF regimen as first-line chemotherapy in metastatic gastric adenocarcinoma: A phase II study
    Chaudhuri, T.
    Babu, K. G.
    Lakshmaiah, K. C.
    Dasappa, L.
    Jacob, L. A.
    Babu, M. C. S.
    Lokesh, K. N.
    Rudresha, A. H.
    Rajeev, L. K.
    Patidar, R.
    Asati, V.
    Chethan, R.
    Koppaka, D.
    Anand, A.
    ANNALS OF ONCOLOGY, 2018, 29
12345